A Phase I Trial of Combined immunotherapy with nivolumab and interferon-beta in Patients with advanced melanoma
Latest Information Update: 14 Dec 2017
Price :
$35 *
At a glance
- Drugs Interferon beta (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 11 Dec 2017 Status changed from recruiting to completed.
- 08 Jul 2016 Status changed from not yet recruiting to recruiting.
- 24 Dec 2015 New trial record